Heron Therapeutics (HRTX) Sets New 1-Year High After Analyst Upgrade
Shares of Heron Therapeutics Inc (NASDAQ:HRTX) hit a new 52-week high during mid-day trading on Monday after ValuEngine upgraded the stock from a sell rating to a hold rating. The stock traded as high as $27.20 and last traded at $27.20, with a volume of 7765660 shares changing hands. The stock had previously closed at $21.50.
Several other analysts have also issued reports on HRTX. Zacks Investment Research upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Wednesday, November 22nd. Cowen restated a “buy” rating and issued a $40.00 price objective on shares of Heron Therapeutics in a report on Wednesday, December 6th. Mizuho restated a “buy” rating and issued a $28.00 price objective on shares of Heron Therapeutics in a report on Friday, December 8th. Oppenheimer set a $27.00 price objective on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Thursday, December 14th. Finally, BidaskClub upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company’s stock. Heron Therapeutics has a consensus rating of “Buy” and a consensus price target of $32.00.
In other Heron Therapeutics news, CEO Barry D. Quart sold 100,000 shares of the business’s stock in a transaction dated Wednesday, March 14th. The shares were sold at an average price of $24.75, for a total transaction of $2,475,000.00. Following the sale, the chief executive officer now directly owns 167,993 shares in the company, valued at $4,157,826.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Kimberly Manhard sold 18,000 shares of the business’s stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $30.00, for a total transaction of $540,000.00. Following the sale, the vice president now owns 18,000 shares in the company, valued at $540,000. The disclosure for this sale can be found here. Insiders have sold 225,584 shares of company stock worth $6,141,680 over the last quarter. Insiders own 19.93% of the company’s stock.
The stock has a market capitalization of $1,389.94, a P/E ratio of -7.46 and a beta of 1.87.
Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.29). Heron Therapeutics had a negative return on equity of 230.70% and a negative net margin of 641.87%. The firm had revenue of $10.05 million for the quarter, compared to analysts’ expectations of $9.00 million. equities research analysts forecast that Heron Therapeutics Inc will post -2.58 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Heron Therapeutics (HRTX) Sets New 1-Year High After Analyst Upgrade” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/03/19/heron-therapeutics-hrtx-sets-new-1-year-high-after-analyst-upgrade.html.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.